We have over 15 years experience in Diversity-Oriented Synthesis (DOS), which aims to efficiently reach and explore broad areas of chemical space. Our world leading experience in computational chemistry enables us to interrogate this repository using state-of-the-art in silico screening programs to identify novel starting points for targets of interest.
Dr. Hannah Sore, Chief Executive Officer
Key roles include: Business strategy and leadership, building customer relations and deal negotiator.
Experience summary: Over 14 years of research expertise, which includes extensive experience within the healthcare and drug discovery sector working in biotechnology, multinational pharmaceutical companies and academia. Over 7 years consulting and business experience across healthcare sectors at Frost & Sullivan and as a founder of HFS Scientific Ltd.
Dr. Natalia Mateu, Chief Scientific Officer
Key roles include: Compound library designer, database manager and medicinal chemistry lead.
Experience summary: Over 10 years of background in organic and medicinal chemistry research, including broad experience in diversity-oriented synthesis of biologically relevant compound collections, target-oriented synthesis of small molecules for drug discovery and several years of expertise in hit-to-lead generation within the pharmaceutical industry.
Lewis Mervin, Head of Technology
Key roles include: Multi-target screening and virtual-screening lead, database and web interface manager.
Experience Summary: Research background in molecular informatics, also known as chem(o)informatics, with expertise in the prediction of properties for small molecules of therapeutic interest (e.g. QSAR and toxicity profiling), including general experience in the analysis of data available in both the biological and chemical domains.
Prof. David Spring, Non-Executive Board and Scientific Avisor
Dave Spring is currently a Professor at the University of Cambridge within the Chemistry Department and a Fellow of Trinity College. He was awarded a Lectureship in 2006, and promoted to a Senior Lectureship in 2008, to a Readership in 2011, and to a Professorship in 2013.
He has over 180 research publications and is a world leader in the area of diversity-oriented synthesis.
Dr. Andreas Bender, Non-Executive Board and Scientific Avisor
Andreas Bender is a Lecturer in Molecular Informatics (also known as Chem(o)informatics) in the Centre for Molecular Sciences Informatics at the University of Cambridge.
In his work, he is focused on the prediction of properties of molecules; here mainly for small molecules (which could be of therapeutic interest), and primarily in the life science field.